GlaxoSmithKline plc. (GSK,GSK.L) and Vir Biotechnology Inc. (VIR) said preclinical data demonstrated that sotrovimab, an investigational monoclonal antibody, retains activity against key mutationsof the new Omicron SARS-CoV-2 variant (B.1.1.529), including those found in the binding site of sotrovimab.
The companies said that the data will be confirmed by further in vitro pseudo-virus testing. They plans to provide an update on it by the end of 2021.
GSK and Vir are also partnering to investigate the use of sotrovimab in uninfected immunocompromised adults to determine whether sotrovimab can prevent symptomatic COVID-19 infection.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.